Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 Immunization Schedule in Healthy Infants
NCT07591181Not yet recruiting
- Sponsor
- Beijing Center for Disease Control and Prevention
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Trial of Prevnar 13 in pneumococcal disease (2 arms), sponsored by Beijing Center for Disease Control and Prevention. Primary endpoint: Seropositivity rate of specific IgG antibodies. Planned start May 2026; status: not yet recruiting.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT07591181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591181.